ArticleGenes and immunity2017
Pre-diagnostic genotyping identifies T1D subjects with impaired Treg IL-2 signaling and an elevated proportion of FOXP3
Open access · greenAbstract read
In one paragraph
Article in Genes and immunity, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Plasticity deficits of Tregs remodeling toward Th1-like and Th17-like Tregs in individuals with type 1 diabetes.Journal of endocrinological investigation · 2025Article
- Targeting CD4+ T Cell Glucose Metabolism: A Novel Immunotherapeutic Approach for Type 1 Diabetes.Biomolecules · 2025Review
- M1 intestinal macrophages-derived exosomes promote colitis progression and mucosal barrier injury.Aging · 2024Article
- Th1 promotes M1 polarization of intestinal macrophages to regulate colitis-related mucosal barrier damage.Aging · 2023Article
- Nature vs. nurture: FOXP3, genetics, and tissue environment shape Treg function.Frontiers in immunology · 2022Review
- Review
- Pathogenic Pathways and Therapeutic Approaches Targeting Inflammation in Diabetic Nephropathy.International journal of molecular sciences · 2020Review
- Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?Journal of clinical medicine · 2020Review
- Cell death pathologies: targeting death pathways and the immune system for cancer therapy.Genes and immunity · 2019Review
- Cell death in cancer in the era of precision medicine.Genes and immunity · 2019Review
- Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases.International journal of molecular sciences · 2019Review
- Article
- Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.Diabetes · 2018Article
- Genetic and epigenetic influences on the loss of tolerance in autoimmunity.Cellular & molecular immunology · 2018Review
- Clinical Applications of Regulatory T cells in Adoptive Cell Therapies.Cell & gene therapy insights · 2018Article
- Abnormal T Cell Frequencies, Including Cytomegalovirus-Associated Expansions, Distinguish Seroconverted Subjects at Risk for Type 1 Diabetes.Frontiers in immunology · 2018Article
- Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state.Clinical immunology (Orlando, Fla.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
A K MarwahaDepartment of Pathology and Laboratory Medicine, University of British Columbia and Child and Family Research Institute, British Columbia Children's Hospital, Vancouver, BC, Canada.
C PanagiotopoulosDepartment of Pediatrics, University of British Columbia and Endocrine and Diabetes Unit, British Columbia Children's Hospital, Vancouver, BC, Canada.
C M BiggsDepartment of Pathology and Laboratory Medicine, University of British Columbia and Child and Family Research Institute, British Columbia Children's Hospital, Vancouver, BC, Canada.
S StaigerDepartment of Pathology and Laboratory Medicine, University of British Columbia and Child and Family Research Institute, British Columbia Children's Hospital, Vancouver, BC, Canada.
K L Del BelDepartment of Pediatrics, University of British Columbia Division of Allergy and Immunology, Vancouver, BC, Canada.
A F HirschfeldDepartment of Pediatrics, University of British Columbia Division of Allergy and Immunology, Vancouver, BC, Canada.
J J PriatelDepartment of Pathology and Laboratory Medicine, University of British Columbia and Child and Family Research Institute, British Columbia Children's Hospital, Vancouver, BC, Canada.
S E TurveyDepartment of Pediatrics, University of British Columbia Division of Allergy and Immunology, Vancouver, BC, Canada.
R TanDepartment of Pathology and Laboratory Medicine, University of British Columbia and Child and Family Research Institute, British Columbia Children's Hospital, Vancouver, BC, Canada.
University of British Columbia · CABC Children's Hospital · CAChild and Family Research Institute · CA
Funding
UCSF CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR024131 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOHNSTON, S. CLAIBORNE · 2006 to 2011
$111.2MType 1 Diabetes Trialnet: Operations Coord. CenterU01DK061055 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI LACHIN, JOHN M · 2001 to 2008
$93.2MUNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9MCTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3MYALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MYOUTH DRUG ABUSE, ADHD, AND RELATED DISRUPTIVE DISORDERSM01RR000400 · NCRR · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BACHANOVA, VERONIKA S · 1985 to 2009
$33.7MNORTH AND CENTRAL TEXAS CTSA FOR PEDIATRIC RESEARCHUL1RR024982 · NCRR · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2007 to 2011
$27.9MStanford Center for Clinical and Translational Education and Research (SCCTER)UL1UL1RR025744 · NCRR · STANFORD UNIVERSITY · PI GREENBERG, HARRY BERNARD · 2008 to 2011
$22.4MLOS ANGELES BASIN CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR031986 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BUCHANAN, THOMAS A · 2010 to 2011
$21.1MINDIANA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE (UL1): BPCAUL1RR025761 · NCRR · INDIANA UNIVERSITY INDIANAPOLIS · PI SHEKHAR, ANANTHA · 2008 to 2011
$21.0MUF CLINICAL AND TRANSLATIONAL SCIENCE AWARDUL1RR029890 · NCRR · UNIVERSITY OF FLORIDA · PI NELSON, DAVID R · 2009 to 2011
$14.4MNCRR NIH HHS M01 RR000400NCRR NIH HHS UL1 RR024131NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1 RR024975NCRR NIH HHS UL1 RR024982NCRR NIH HHS UL1 RR025744NCRR NIH HHS UL1 RR025761NCRR NIH HHS UL1 RR025780NCRR NIH HHS UL1 RR029890NCRR NIH HHS UL1 RR031986NIDDK NIH HHS U01 DK061010NIDDK NIH HHS U01 DK061034NIDDK NIH HHS U01 DK061036NIDDK NIH HHS U01 DK061040NIDDK NIH HHS U01 DK061041NIDDK NIH HHS U01 DK061042NIDDK NIH HHS U01 DK061055NIDDK NIH HHS U01 DK061058NIDDK NIH HHS U01 DK085453NIDDK NIH HHS U01 DK085461NIDDK NIH HHS U01 DK085463NIDDK NIH HHS U01 DK085466NIDDK NIH HHS U01 DK085499NIDDK NIH HHS U01 DK085505NIDDK NIH HHS U01 DK085509
Abstract
T-regulatory cells (Tregs) are essential for immune tolerance, and animal studies implicate their dysfunction in type 1 diabetes (T1D) pathogenesis. Tregs require interleukin-2 (IL-2) for their suppressive function, and variants in IL-2/IL-2R pathway genes have been associated with T1D. We previously reported that recent-onset T1D subjects have an increased population of FOXP3
Indexed as
BiomarkersDiabetes Mellitus, Type 1Flow CytometryForkhead Transcription FactorsGenotypeHumansImmune ToleranceInterleukin-17Interleukin-2PrognosisSignal TransductionTh17 CellsT-Lymphocytes, RegulatoryBiomarkersForkhead Transcription FactorsFOXP3 protein, humanIL17A protein, humanInterleukin-17Interleukin-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.